Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next?
Version of Record online: 12 JUL 2005
Alimentary Pharmacology & Therapeutics
Volume 22, Issue 2, pages 79–94, July 2005
How to Cite
FASS, R., SHAPIRO, M., DEKEL, R. and SEWELL, J. (2005), Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next?. Alimentary Pharmacology & Therapeutics, 22: 79–94. doi: 10.1111/j.1365-2036.2005.02531.x
- Issue online: 12 JUL 2005
- Version of Record online: 12 JUL 2005
- Accepted for publication 30 April 2005
- 1‘Refractory GERD’: acid, nonacid, or not GERD? Am J Gastroenterol 2004; 99: 989–90..Direct Link:
- 2Oral pantoprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071–80., .Direct Link:
- 4Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI (abstract). Gastroenterology 2004; 146: A-37 (no. 326)., , , .
- 5Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy – a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595–603., , , et al.
- 7Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completed relieved with PPIs. Am J Gastroenterol 2003; 98: 1940–4., , , .Direct Link:
- 9How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study. JCOM 2000; 7: 29–34., .
- 13Rabeprazole in nonerosive gastro-oesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332–9., , , , .Direct Link:
- 15A high overlap in esophageal acid exposure between the gastro-oesophageal reflux disease (GERD) groups supports distinct phenotypic presentations rather than the spectrum continuum model (abstract). Gastroenterology 2005; 128: A384, M1748., , , .
- 16Functional esophageal disorders. In: Drossman, DA, Corazziari, E, Talley, NJ, Thompson, WG, Whitehead, WE, The Rome II Multinational Working Teams, eds. Rome II The Functional Gastrointestinal Disorders, 2nd edn. Lawrence, KS, USA: Allen Press Inc., 2000: 275., , , , .
- 23Efficacy and safety of esomeprazole compared to omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65., , , et al.Direct Link:
- 27Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1998; 93: 711–6., .Direct Link:
- 29Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's oesophagus. Am J Gastroenterol 2004; 99: 1877–83., , , , , .Direct Link:
- 34The Gallup Organization. Gallup Study of Consumers’ Use of Stomach Relief Products. Princeton, NJ: The Gallup Organization, 2000.
- 39The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; 3: 315–20., , , , , .
- 41Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump (abstract). Gastroenterology 1995; 108: A147., , , , .
- 46CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17: 1521–18., , , , , .
- 47Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763–7., , , .Direct Link:
- 48Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545–50., , , .Direct Link:
- 52Duodenogastroesopahgeal reflux. In: Castell, DO, Richter, JE, eds. The Oesophagus, 4th edn. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2004: 434–50..
- 53Assessment of non-acid esophageal reflux: comparison between long-term reflux aspiration test and fiberoptic bilirubin monitoring. Dis Oesophagus 1997; 10: 24–8., , , , .
- 57Gastro-oesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's oesophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 981–8., , , , .Direct Link:
- 62The role of esophageal afferent pathway sensitivity in non-erosive reflux disease (abstract). Gastroenterology 2004; 126: A-18 (no. 128)., , , .
- 66Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy (abstract). Neurogastroenterol Motil 2004; 16: 654 (no. 23)., , , .
- 70Declining diagnostic utility of upper endoscopy in patients with gastro-oesophageal reflux disease (abstract). Gastrointest Endosc 2002; 55: AB89 (no. 459)., , , , .
- 72Persistent symptoms of heartburn in patients on standard doses of proton pump inhibitors (PPI) are not due to acid reflux in most patients (abstract). Gastroenterology 1999; 116: A160 (no. G0694)., , , .
- 73A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngopharyngeal reflux (abstract). Gastroenterology 2004; 126: A22 (no. 160)., , , et al.
- 74Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740–9., , , , , .Direct Link:
- 81Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol 1999; 2: 348–56..
- 88Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089–98., , , , , .Direct Link: